New! Sign up for our free email newsletter.
Science News
from research organizations

The promising drug duo that may improve spinal muscular atrophy (SMA) treatment

Date:
July 13, 2022
Source:
Cold Spring Harbor Laboratory
Summary:
In 2016, Spinraza became the first FDA-approved treatment for spinal muscular atrophy. Researchers have found a way the therapeutic effects of Spinraza may be improved. They discovered that pairing Spinraza with a second FDA-approved drug called valproic acid may help optimize Spinraza's efficiency.
Share:
FULL STORY

In 2016, Spinraza® became a game-changer for spinal muscular atrophy (SMA) patients. It was the first FDA-approved treatment for the neurodegenerative disease, which is the leading genetic cause of infant death. The drug was conceived and developed by Cold Spring Harbor Laboratory (CSHL) Professor Adrian Krainer and collaborators. But Krainer didn't stop there. His lab has been investigating whether Spinraza® could be improved, in collaboration with Alberto Kornblihtt at Universidad de Buenos Aires. They discovered pairing Spinraza® with a second FDA-approved drug called valproic acid (VPA) could be a new way to boost its therapeutic effects.

One way to improve the effect of a drug is by increasing its dosage. But as with any drug, increasing the amount of Spinraza® also increases the risk of toxic side effects. Krainer and collaborators took a different approach. They discovered that pairing Spinraza® with VPA may be an alternate way to improve its clinical effect without using more of the drug. Krainer explains:

"Sometimes you don't want to use a ton of a drug. If you have a condition that allows you to use less drug, then you may have fewer toxicities. So the idea is to combine these two drugs to get maximal effects."

People with SMA don't have enough of a protein called SMN. Spinraza® is a type of molecule called an antisense oligonucleotide (ASO) that helps cells make more SMN protein from a gene called SMN2. The team discovered that there were roadblocks on the SMN2 gene when using Spinraza®. This slowed down the cellular machine producing SMN protein. The drug VPA helps remove the roadblocks, allowing Spinraza® to further increase the SMN protein output. When mice with SMA were treated with both VPA and a Spinraza®-like ASO used for research, the mice survived longer and had improved muscle function.

Over 11,000 SMA patients have been treated with Spinraza® in more than 50 countries. Krainer's latest research shows that there's always room for improvement. He hopes the team's findings will help optimize the efficacy of Spinraza® treatments. He also hopes their work will help researchers who are trying to develop therapies for other neurodegenerative diseases.


Story Source:

Materials provided by Cold Spring Harbor Laboratory. Original written by Luis Sandoval. Note: Content may be edited for style and length.


Journal Reference:

  1. Luciano E. Marasco, Gwendal Dujardin, Rui Sousa-Luís, Ying Hsiu Liu, Jose N. Stigliano, Tomoki Nomakuchi, Nick J. Proudfoot, Adrian R. Krainer, Alberto R. Kornblihtt. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy. Cell, 2022; 185 (12): 2057 DOI: 10.1016/j.cell.2022.04.031

Cite This Page:

Cold Spring Harbor Laboratory. "The promising drug duo that may improve spinal muscular atrophy (SMA) treatment." ScienceDaily. ScienceDaily, 13 July 2022. <www.sciencedaily.com/releases/2022/07/220713114614.htm>.
Cold Spring Harbor Laboratory. (2022, July 13). The promising drug duo that may improve spinal muscular atrophy (SMA) treatment. ScienceDaily. Retrieved March 27, 2024 from www.sciencedaily.com/releases/2022/07/220713114614.htm
Cold Spring Harbor Laboratory. "The promising drug duo that may improve spinal muscular atrophy (SMA) treatment." ScienceDaily. www.sciencedaily.com/releases/2022/07/220713114614.htm (accessed March 27, 2024).

Explore More

from ScienceDaily

RELATED STORIES